Lipocine Inc. (LPCN)
Lipocine Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Lipocine Inc. (LPCN) is a Biotechnology company based in US with a market capitalization of $12.1M. Revenue declined 82.3% year-over-year and free cash flow was negative at -$9.8M. This page tracks LPCN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 16 employees · IPO Oct 22, 2013
Valuation
Valuation & price
$2.26as of May 17, 2026· -79.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.83
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$12.1M
Market cap
-82.3%
Revenue growth (YoY)
-334.3%
Gross margin
-$9.8M
Free cash flow (USD)
-$14.9M
Net debt
Net cash position
2.1%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 12, 2026Filing
KOL Event Hosted
- 8-K eventJun 4, 2026Filing
Virtual KOL Event Announcement
- 8-K eventJun 4, 2026Filing
Stock Incentive Plan Update
- 8-K eventMay 26, 2026Filing
Clinical Data Presentation
- 8-K eventMay 19, 2026Filing
Phase 3 Data Presentation
- 8-K eventMay 18, 2026Filing
Presentation Announcement
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
Earnings Release
- 8-K eventMay 7, 2026Filing
Corporate Presentation Update
- 8-K eventApr 21, 2026Filing
Director Resignation
Questions
Frequently asked questions
What is Lipocine Inc.'s market cap?
Lipocine Inc. (LPCN) has a market capitalization of $12.1M.
What is LPCN's P/E ratio?
A meaningful P/E ratio is not available for LPCN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is LPCN's price-to-book (P/B) ratio?
LPCN trades at 0.83 times book value per share.
Are insiders buying LPCN stock?
SEC Form 4 filings show no open-market insider buys at Lipocine Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.